Strongbridge Biopharma plc SBBP:NASDAQ

RT Quote | NASDAQ | USD
Last | 03/04/21 EST
2.77quote price arrow down-0.10 (-3.48%)
Volume
1,506,462
52 week range
1.50 - 4.63

...

Loading . . .

KEY STATS

  • Open2.98
  • Day High3.03
  • Day Low2.62
  • Prev Close2.77
  • 52 Week High4.63
  • 52 Week High Date06/19/20
  • 52 Week Low1.50
  • 52 Week Low Date03/19/20
  • Market Cap186.25M
  • Shares Out67.24M
  • 10 Day Average Volume1.05M
  • Dividend-
  • Dividend Yield-
  • Beta1.71
  • 1 Year % Change-3.15

RATIOS/PROFITABILITY

  • EPS (TTM)-0.79
  • P/E (TTM)-3.52
  • Fwd P/E (NTM)-6.92
  • EBITDA (MRQ)-44.25M
  • ROE (MRQ)-54.61%
  • Revenue (MRQ)28.11M
  • Gross Margin (MRQ)90.20%
  • Net Margin (MRQ)-149.80%
  • Debt To Equity (MRQ)9.75%

EVENTS

  • Earnings Date05/06/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Strongbridge Biopharma plc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a...
John Johnson
Chief Executive Officer
Richard Kollender CPA
President
Robert Lutz
Chief Financial Officer
Address
900 Northbrook Dr Ste 200
Trevose, PA
19053-8433
United States